



Novel Biomarkers and Molecular Targets in Cancer

Guest Editor:

Dr. Anna Kakehashi

Department of Molecular
Pathology, Graduate School of
Medicine, Osaka Metropolitan
University, Osaka 545-8585,
Japan

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Today, the discovery of novel biomarkers and molecular targets to fight cancer remains the matter of great importance. Recent novel techniques, including cancer mutational analysis, genomics, proteomics and metabolomics, have given rise to new efforts in performing pathological, biochemical, molecular, and immunological research to study the mechanisms of carcinogenesis, with the final aim of finding the cancer molecular targets, which could be applied in clinical practice. This Special Issue aims to present the most recent studies related to the discovery of novel biomarkers and molecular targets in various cancers. The research could be performed in different aspects, including: 1) genetic alterations in cancer, 2) diagnosis using novel techniques, 3) cancer molecular mechanisms, 4) in vitro and in vivo carcinogenesis models for the discovery of cancer risk factors and innovative drugs to treat cancer, 5) cancer metabolic and proteomic signatures and altered pathways, 6) stem, stromal and immune cell biomarkers in cancer, and 7) preclinical innovative studies.

Dr. Anna Kakehashi

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)